A Phase I/II Clinical Trial of Combination of Irinotecan, Xeloda and Oxaliplatin (IXO) Regimen With Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Phase I: Assess the MTD and RD for phase II of IXO and bevacizumab combination given every 3 weeks in 1st line patients with mCRC
3-week cycle, continuous monitoring of AE
Yes
Jean Maroun, MD
Principal Investigator
The Ottawa Hospital Cancer Centre
Canada: Health Canada
0TT 03-03
NCT00819754
November 2003
July 2013
Name | Location |
---|